LBJ Family Wealth Advisors Ltd. cut its position in Reata Pharmaceuticals Inc (NASDAQ:RETA) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 53,404 shares of the company’s stock after selling 7,371 shares during the period. Reata Pharmaceuticals comprises about 2.6% of LBJ Family Wealth Advisors Ltd.’s portfolio, making the stock its 10th largest position. LBJ Family Wealth Advisors Ltd. owned approximately 0.18% of Reata Pharmaceuticals worth $2,996,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in shares of Reata Pharmaceuticals by 276.8% during the third quarter. Tower Research Capital LLC TRC now owns 1,398 shares of the company’s stock worth $114,000 after acquiring an additional 1,027 shares during the period. Lee Financial Co acquired a new stake in shares of Reata Pharmaceuticals during the third quarter worth $128,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Reata Pharmaceuticals during the second quarter worth $154,000. First Mercantile Trust Co. acquired a new stake in shares of Reata Pharmaceuticals during the third quarter worth $167,000. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Reata Pharmaceuticals by 53.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock worth $191,000 after acquiring an additional 1,897 shares during the period. Institutional investors own 52.85% of the company’s stock.
A number of brokerages recently commented on RETA. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 28th. BidaskClub lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 15th. Cantor Fitzgerald set a $100.00 price target on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 7th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $133.00 price objective on shares of Reata Pharmaceuticals in a research report on Wednesday, September 26th. Finally, Leerink Swann reissued an “outperform” rating and issued a $139.00 price objective (up previously from $116.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, September 25th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $100.33.
Shares of RETA opened at $72.49 on Friday. Reata Pharmaceuticals Inc has a one year low of $19.31 and a one year high of $99.50. The stock has a market capitalization of $2.09 billion, a PE ratio of -36.43 and a beta of 2.84. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 2.10.
Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.28). The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $9.50 million. On average, research analysts forecast that Reata Pharmaceuticals Inc will post -3.08 earnings per share for the current fiscal year.
In related news, insider Keith Wayne Ward sold 4,150 shares of Reata Pharmaceuticals stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $53.99, for a total transaction of $224,058.50. Following the completion of the sale, the insider now owns 4,150 shares of the company’s stock, valued at approximately $224,058.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jason Douglas Wilson sold 20,000 shares of Reata Pharmaceuticals stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $72.04, for a total transaction of $1,440,800.00. Following the sale, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,440,800. The disclosure for this sale can be found here. In the last three months, insiders bought 171,410 shares of company stock valued at $10,141,332 and sold 47,900 shares valued at $3,078,886. Company insiders own 31.69% of the company’s stock.
WARNING: This report was first published by Fairfield Current and is owned by of Fairfield Current. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.fairfieldcurrent.com/news/2019/01/11/lbj-family-wealth-advisors-ltd-has-3-million-holdings-in-reata-pharmaceuticals-inc-reta.html.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Reata Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Reata Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.